Loading clinical trials...
Loading clinical trials...
A Dose-Escalation, Randomized Phase I/II Trial of Zalutumumab - a Human Monoclonal Anti-EGF Receptor Antibody - With or Without Irinotecan Chemotherapy in Cetuximab Refractory Colorectal Cancer Patients Who Have Failed Standard Chemotherapy and Progressed During or Within 3 Months of Stopping Cetuximab-Based Therapy
The purpose of this trial is to determine the safety and efficacy of Zalutumumab alone or in combination with Irinotecan for the treatment of patients with Colorectal Cancer
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Institut Jules Bordet
Brussels, Belgium
Hospital Erasme
Brussels, Belgium
St-Luc University Hospital
Brussels, Belgium
Start Date
April 1, 2008
Primary Completion Date
April 1, 2009
Completion Date
April 1, 2009
Last Updated
July 18, 2023
9
ACTUAL participants
Zalutumumab
DRUG
Lead Sponsor
Genmab
NCT04704661
NCT06696768
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions